Antonio Maraver

Dr. Antonio Maraver

Oncogenic Pathways in Lung Cancer, Institut de Recherche en Cancérologie de Montpellier, Inserm U1194 - Université Montpellier - ICM, Campus Val d'Aurelle, 208 Rue des Apothicaires, CEDEX 5, F-34298 Montpellier, France
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Cell
Verified
Journal Article
Closed access
DMDaniel Muñoz-Espín
Daniel Muñoz-Espín
MCMarta Cañamero
Marta Cañamero
Antonio MaraverAntonio Maraver
Antonio Maraver
Gonzalo Gomez-LopezGonzalo Gomez-Lopez
Gonzalo Gomez-Lopez
JCJulio Contreras
Julio Contreras
MSManuel Serrano
Manuel Serrano

13 March 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CTCarlos E. Tadokoro
Carlos E. Tadokoro
GSGuy Shakhar
Guy Shakhar
SSShiqian Shen
Shiqian Shen
YDYi Ding
Yi Ding
ALAndreia C. Lino
Andreia C. Lino
MDMichael Dustin
Michael Dustin
Regulatory T (T reg) cells exert powerful down-modulatory effects on immune responses, but it is not known how they act in vivo. Using intravital two-photon laser scanning microscopy we determined that, in the absence of T reg cells, the locomotion of autoantigen-specific T cells inside lymph nodes is decreased, and the contacts between T cells and antigen-loaded dendritic cells (DCs) are of longer duration. Thus, T reg cells can exert an early effect on immune responses by attenuating the establishment of stable contacts during priming of naive T cells by DCs.

1 November 2008 in Cell
Verified
Journal Article
Closed access
ATAntonia Tomás-Loba
Antonia Tomás-Loba
IFIgnacio Flores
Ignacio Flores
PFPablo J. Fernández-Marcos
Pablo J. Fernández-Marcos
MCMaría L. Cayuela
María L. Cayuela
Antonio MaraverAntonio Maraver
Antonio Maraver
MBMaria A. Blasco
Maria A. Blasco

1 July 2007 in Nature
Verified
Journal Article
Closed access
PDF file
AMAnder Matheu
Ander Matheu
Antonio MaraverAntonio Maraver
Antonio Maraver
PKPeter Klatt
Peter Klatt
IFIgnacio Flores
Ignacio Flores
IGIsabel Garcia-Cao
Isabel Garcia-Cao
MSManuel Serrano
Manuel Serrano

1 August 2012 in Cancer Cell
Verified
Journal Article
Closed access
Antonio MaraverAntonio Maraver
Antonio Maraver
PFPablo J. Fernandez-Marcos
Pablo J. Fernandez-Marcos
DHDaniel Herranz Herranz
Daniel Herranz Herranz
MCMarta Cañamero
Marta Cañamero
MMMaribel Muñoz-Martin
Maribel Muñoz-Martin
MSManuel Serrano
Manuel Serrano

9 January 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Antonio MaraverAntonio Maraver
Antonio Maraver
PFPablo J. Fernandez-Marcos
Pablo J. Fernandez-Marcos
TCTimothy P. Cash
Timothy P. Cash
MMMarinela Mendez-Pertuz
Marinela Mendez-Pertuz
MDMarta Dueñas
Marta Dueñas
MSManuel Serrano
Manuel Serrano
NOTCH signaling suppresses tumor growth and proliferation in several types of stratified epithelia. Here, we show that missense mutations in NOTCH1 and NOTCH2 found in human bladder cancers result in loss of function. In murine models, genetic ablation of the NOTCH pathway accelerated bladder tumorigenesis and promoted the formation of squamous cell carcinomas, with areas of mesenchymal features. Using bladder cancer cells, we determined that the NOTCH pathway stabilizes the epithelial phenotype through its effector HES1 and, consequently, loss of NOTCH activity favors the process of epithelial-mesenchymal transition. Evaluation of human bladder cancer samples revealed that tumors with low levels of HES1 present mesenchymal features and are more aggressive. Together, our results indicate that NOTCH serves as a tumor suppressor in the bladder and that loss of this pathway promotes mesenchymal and invasive features.